Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.19 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LAVI On Other Exchanges
As of 10:10 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

lavipharm s.a. (LAVI) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/5/15 - €0.19
52 Week Low
01/16/15 - €0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LAVIPHARM S.A. (LAVI)

Related News

No related news articles were found.

lavipharm s.a. (LAVI) Related Businessweek News

No Related Businessweek News Found

lavipharm s.a. (LAVI) Details

Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, general medicine, gastrointestinal system, and urology. It also provides over the counter (OTC) drugs, including antiseptics, analgesics, gastrointestinal, gynecological, and dermatological products, as well as OTC drugs for anti-lice treatment; and dermocosmetics products for skincare. In addition, the company offers Trinipatch, a nitroglycerine transdermal delivery system used for the prevention of angina. Further, its product pipeline includes nicotine transdermal system (TDDS) for smoking cessation; TDDS for hypertension; product lines for intensive care, such as anti-ageing products; and various OTC products for the symptoms of common cold, oral hygiene, and excessive excretion of shawl, as well as food supplements. It serves health professionals, physicians and pharmacists. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece.

Founded in 1911

lavipharm s.a. (LAVI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lavipharm s.a. (LAVI) Key Developments

Lavipharm Announces Consolidated Earnings Results for the First Half of 2015

Lavipharm announced consolidated earnings results for the first half of 2015. For the first half, the company reported sales of EUR 13 million, compared with EUR 14.8 million in the first half of 2014. The company recorded an increase in EBITDA, with the total reaching EUR 1.3 million, compared with LBITDA of EUR 7.4 million in the first half of 2014. The group's net loss was EUR 4.7 million, compared with a net loss of EUR 21.5 million in the equivalent period last year.

Lavipharm S.A., Annual General Meeting, Jun 30, 2015

Lavipharm S.A., Annual General Meeting, Jun 30, 2015., at 14:00 E. Europe Standard Time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LAVI:GA €0.19 EUR 0.00

LAVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LAVI.
View Industry Companies

Industry Analysis


Industry Average

Valuation LAVI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LAVIPHARM S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at